Drug Trial Radar · NCT06934382
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
33
Planned (sponsor's estimate)
Start
Apr 29, 2025
Primary completion
May 30, 2029
Study completion May 30, 2031
Sponsor
- Lead sponsor
- Stephan Grupp MD PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Beam Therapeutics Inc.
- First posted
- Apr 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 29 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
Conditions
- T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Interventions
Allogeneic anti-CD7 CAR-T cells (BEAM-201)Biological
The investigational agent in this protocol is allogeneic anti-CD7 CART cells (BEAM-201). BEAM-201 is comprised of allogeneic anti-CD7 CAR-T cells edited by 4 gRNAs and a single mRNA encoding a CBE, then transduced with a lentiviral vector (LVV) encoding the anti-CD7 chimeric antigen receptor (CAR) molecule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the Maximum Tolerate Dose of Beam 201 CellsTime frame: 5 years
- Frequency of Adverse Events Following Beam-201 administrationTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.